0000000000673684

AUTHOR

Joan Albert Barberà

showing 3 related works from this author

Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching

2017

Introduction Current treatment with vasodilators for pulmonary hypertension associated with respiratory diseases is limited by their inhibitory effect on hypoxic pulmonary vasoconstriction (HPV) and uncoupling effects on ventilation-perfusion (V'/Q'). Hypoxia is also a well-known modulator of the nitric oxide (NO) pathway, and may therefore differentially affect the responses to phosphodiesterase 5 (PDE5) inhibitors and soluble guanylyl cyclase (sGC) stimulators. So far, the effects of the sGC stimulator riociguat on HPV have been poorly characterized. Materials and methods Contraction was recorded in pulmonary arteries (PA) in a wire myograph. Anesthetized rats were catheterized to record …

MaleAnoxemiaPulmonologyPulmonary FibrosisVasodilator Agentslcsh:MedicineVasodilation030204 cardiovascular system & hematologyPharmacologyVascular Medicinechemistry.chemical_compound0302 clinical medicineSoluble Guanylyl CyclaseHypoxic pulmonary vasoconstrictionPulmonary fibrosisMedicine and Health SciencesPulmonary Arterieslcsh:ScienceHypoxiaMultidisciplinaryVasodilatorsDrugsRespiratory organs diseasesArteriesMiddle AgedChemistryPhysical Sciencescardiovascular systemFemalemedicine.symptomAnatomyMedicamentsmedicine.drugResearch ArticleChemical Elementsinorganic chemicalsSildenafilHypertension PulmonaryChronic Obstructive Pulmonary DiseaseEnzyme ActivatorsIn Vitro TechniquesPulmonary ArteryRiociguatSildenafil CitrateMalalties de l'aparell respiratori03 medical and health sciencesMedical HypoxiamedicineVentilation-Perfusion RatioAnimalsHumansRats WistarAgedPharmacologybusiness.industrylcsh:RAnoxèmiaBiology and Life SciencesHypoxia (medical)Phosphodiesterase 5 Inhibitorsmedicine.diseasePulmonary hypertensionFibrosisRatsOxygenDisease Models AnimalPyrimidines030228 respiratory systemchemistryVasoconstrictionCardiovascular AnatomyPyrazolesBlood Vesselslcsh:QSoluble guanylyl cyclasebusinessDevelopmental Biology
researchProduct

Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases

2017

The European Respiratory Society (ERS) Research Seminar entitled “Pulmonary vascular endothelium: orchestra conductor in respiratory diseases - highlights from basic research to therapy” brought together international experts in dysfunctional pulmonary endothelium, from basic science to translational medicine, to discuss several important aspects in acute and chronic lung diseases. This review will briefly sum up the different topics of discussion from this meeting which was held in Paris, France on October 27–28, 2016. It is important to consider that this paper does not address all aspects of endothelial dysfunction but focuses on specific themes such as: 1) the complex role of the pulmon…

Pulmonary and Respiratory MedicineParismedicine.medical_specialtyEndotheliumRespiratory Tract DiseasesRespiratory SystemDysfunctional familyDiseasePulmonary ArteryVascular Remodeling030204 cardiovascular system & hematologyLung injury03 medical and health sciences0302 clinical medicinemedicineHumansEndothelial dysfunctionIntensive care medicineLungbusiness.industryTranslational medicine11 Medical And Health SciencesCongresses as Topicmedicine.diseasePulmonary hypertensionmedicine.anatomical_structure030228 respiratory systemDrug DesignEndothelium VascularbusinessEuropean Respiratory Journal
researchProduct

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

2021

OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping ri…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyRegistryMedDRAPeripheral edemaClinical practicePulmonary arterial hypertensionRiociguatlaw.inventionPulmonary hypertension03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicine030212 general & internal medicineAdverse effectHipertensió pulmonarRiociguatbusiness.industrymedicine.diseasePulmonary hypertensionClinical trial030228 respiratory systemPulmonary hemorrhagemedicine.symptomSafetybusinessmedicine.drug
researchProduct